Resumen:
HIV-1 R5 viruses predominantly use CCR5 as a coreceptor to infect CD4+ T cells and macrophages.
While R5 viruses generally infect CD4+ T cells, research over the past few years has demonstrated
that they vary extensively in their capacity to infect macrophages. Thus, R5 variants that are highly
macrophage tropic have been detected in late disease and are prominent in brain tissue of subjects
with neurological complications. Other R5 variants that are less sensitive to CCR5 antagonists and
use CCR5 differently have also been identified in late disease. These latter variants have faster
replication kinetics and may contribute to CD4 T-cell depletion. In addition, R5 viruses are highly
variable in many other properties, including sensitivity to neutralizing antibodies and inhibitors that
block HIV-1 entry into cells. Here, we review what is currently known about how HIV-1 R5 viruses
vary in cell tropism and other properties, and discuss the implications of this variation on
transmission, pathogenesis, therapy and vaccines.